2,052 Hits in 8.9 sec

Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer

Morgan Craig, Kamran Kaveh, Alec Woosley, Andrew S. Brown, David Goldman, Elliot Eton, Ravindra M. Mehta, Andrew Dhawan, Kazuya Arai, M. Mamunur Rahman, Sidi Chen, Martin A. Nowak (+2 others)
2019 PLoS Computational Biology  
Here, we report a previously unrecognized behavior in heterogeneous tumors: cooperative adaptation to therapy (CAT), in which cancer cells induce co-resistant phenotypes in neighboring cancer cells when  ...  Using a CRISPR/Cas9 toolkit we engineered phenotypically diverse non-small cell lung cancer (NSCLC) cells by conferring mutations in Dicer1, a type III cytoplasmic endoribonuclease involved in small non-coding  ...  Acknowledgments The authors would like to thank Dr. Jeff Gore and Dr.  ... 
doi:10.1371/journal.pcbi.1007278 pmid:31449515 pmcid:PMC6709889 fatcat:3btkgpyngzgw5bfzzbwq6zh6te

Tracheostomy protocol compliance: Herding cats?*

Linda Liu, Michael A. Gropper
2008 Critical Care Medicine  
Pharmacologic preconditioning with levosimendan is currently known to represent a powerful cell-protective mechanism conferring relative resistance against cell death.  ...  Cooper et al.  ...  Tables 1 and 2 provide my current opinions on use of steroid therapy in ARDS and septic shock, respectively. R. Phillip Dellinger, MD, FCCM Cooper Health Systems -Critical Care Section Camden, NJ  ... 
doi:10.1097/ccm.0b013e3181761228 pmid:18520651 fatcat:a7js773jyrdpjn25oafe7xsiaa

The role of memory in non-genetic inheritance and its impact on cancer treatment resistance

Tyler Cassidy, Daniel Nichol, Mark Robertson-Tessi, Morgan Craig, Alexander R. A. Anderson, Dominik Wodarz
2021 PLoS Computational Biology  
We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population  ...  Consequently, understanding the role of this plasticity in treatment resistance and failure is a key component of improving cancer therapy.  ...  Acknowledgments Portions of this work were completed while TC, DN, and ARAA participated in the thematic semester in Mathematical Biology at the Institut Mittag-Leffler.  ... 
doi:10.1371/journal.pcbi.1009348 pmid:34460809 pmcid:PMC8432806 fatcat:kx6yovmdx5byzbpy7r3h7hdsii

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

Rita Sulahian, Jason J. Kwon, Katherine H. Walsh, Emma Pailler, Timothy L. Bosse, Maneesha Thaker, Diego Almanza, Joshua M. Dempster, Joshua Pan, Federica Piccioni, Nancy Dumont, Alfredo Gonzalez (+19 others)
2019 Cell Reports  
We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS-mutant pancreatic and lung cancer cell lines and identified genes that cooperate with  ...  cancer cells.  ...  SHOC2 confers a selectively potent sensitization of KRAS mutant lung cancer cells to MEKi.  ... 
doi:10.1016/j.celrep.2019.08.090 pmid:31577942 pmcid:PMC6918830 fatcat:ttlatrftrraybo7dbs72uiljbq

Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors

N. An, Y. Xiong, A. C. LaRue, A. S. Kraft, B. Cen
2015 Cancer Research  
This resistance mechanism was documented in non-small cell lung cancer and gastric cancer cells with MET amplification.  ...  Protein synthesis was increased in drug-resistant cells, secondary to a Pim-mediated increase in cap-independent translation.  ...  Further work will be needed to determine the cooperative role Pim activation plays with other genetic and genomic alterations to induce resistance to MET inhibitors in lung, gastric, and other cancers.  ... 
doi:10.1158/0008-5472.can-15-0544 pmid:26670562 pmcid:PMC4683614 fatcat:7yoxer4x6zh6thh5u6uqp4k4xq

Concomitant Diffuse Pulmonary Carcinoma and Chronic Interstitial Pneumonia in a Cat with Hypertrophic Cardiomyopathy: Unusual Pathological Findings and Differential Diagnosis

M. Romanucci, M. Massimini, G. Aste, S.V.P. Defourny, P.E. Crisi, L. Della Salda
2017 Journal of Comparative Pathology  
To the best of our knowledge, this is the first description of an esophageal embryonal rhabdomyosarcoma in a dog. NOTES  ...  Embryonal rhabdomyosarcomas occur in 23% of canine cases and are most commonly reported in the head and neck region.  ...  Introduction: In human breast cancer, Phosphatidylinositol-3 kinase (PI3K) mutation is involved in tumour growth and resistance to hormone therapy.  ... 
doi:10.1016/j.jcpa.2016.11.220 fatcat:uqdkroslvfewbo4vugk5beuhji

Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors

Yunhua Xu, Qunxiong Pan, Chongren Wang, Chunya He, Zijian Su, Xiaowei Guo, Jian Zhang, Min Kong, Shaoying Ke, Jianhua Zhang, Baofu Chen, Haihui Sheng (+1 others)
2014 American Journal of Cancer Research  
The aim of this study was to examine the effect of 20 single nucleotide polymorphisms (SNPs) in 20 oxidative stress-related genes on clinical outcome in 219 patients with advanced non-small cell lung cancer  ...  Many types of cancer have high antioxidant capacity that effectively scavenges reactive oxygen species and thus protect cancer cells against oxidative damage.  ...  Approximately 85% of lung cancers are non-small cell lung cancer (NSCLC) [2] . An activating mutation of epidermal growth factor receptor (EGFR) is present in 40.9% of NSCLC [3] .  ... 
pmid:25520881 pmcid:PMC4266725 fatcat:izqj7jyhjrbddpyxycgrriwsee

Discrete Adaptive Responses to MEK Inhibitor in Subpopulations of Triple-Negative Breast Cancer

Daniel R. Goulet, Joseph P. Foster, Jon S Zawistowski, Samantha M. Bevill, Melodie P. Noel, Jose F. Olivares-Quintero, Noah Sciaky, Darshan Singh, Charlene Santos, Samantha G Pattenden, Ian J. Davis, Gary L. Johnson
2020 Molecular Cancer Research  
RNAi knockdown of CXCR7 inhibited proliferation in trametinib resistant cells. Thus, adaptive resistance to chronic trametinib treatment contributes to proliferation in the presence of the drug.  ...  Adaptive followed by acquired gene expression changes contributed to proliferation in trametinib resistant cells, suggesting inhibition of early transcriptional reprogramming could prevent resistance and  ...  Deep sequencing and the development of molecular subtypes have improved initial diagnosis, but tumors can carry pre-existing secondary mutations that confer resistance to therapy, leading to non-durable  ... 
doi:10.1158/1541-7786.mcr-19-1011 pmid:32753473 pmcid:PMC7642176 fatcat:xis573nzrfaepgwwqaorbkpkj4

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Weiqiang Zhou, Shanchun Guo, Mingli Liu, Matthew E. Burow, Guangdi Wang
2017 Current Medicinal Chemistry  
CSCs are a small population of tumor cells that possess the stem cell property and initiate, drive carcinogenesis contributing to tumor cellular heterogeneity [93][94][95]. Many cancers Zhou et al.  ...  CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1, also known as CXCL12), which has been found to be expressed in more than 23 different types of cancers.  ...  ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013; 328(1):144-151. [PubMed: 22935675] 102.  ... 
doi:10.2174/0929867324666170830111531 pmid:28875842 pmcid:PMC5949083 fatcat:5ans3i6xcvcufmhekx73boi3iq

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma

Ahmad Najem, Laura Soumoy, Malak Sabbah, Mohammad Krayem, Ahmad Awada, Fabrice Journe, Ghanem E. Ghanem
2022 Cells  
Melanoma cells are notorious for their high plasticity and ability to switch back and forth between various melanoma cell states, enabling the adaptation to sub-optimal conditions and therapeutics.  ...  This phenotypic plasticity, which has gained more attention in cancer research, is proposed as a new paradigm for melanoma progression.  ...  Cells 2022, 11, 1157  ... 
doi:10.3390/cells11071157 pmid:35406721 pmcid:PMC8997563 fatcat:i2p747s2mfa2jmnixboxrqzdea

The role of memory in non-genetic inheritance and its impact on cancer treatment resistance [article]

Tyler Cassidy, Daniel Nichol, Mark Robertson-Tessi, Morgan Craig, Alexander R.A. Anderson
2021 bioRxiv   pre-print
We further use our model to study the role of phenotypic heterogeneity in therapeutic resistance in a genetically identical non-small cell lung cancer population.  ...  We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population  ...  therapies to prevent phenotypic switching. 224 Avoiding resistance to therapy in NSCLC 225 226 non-small cell lung cancer (NSCLC) accounts for 20% of all cancer-related deaths [50]. 227 Nearly  ... 
doi:10.1101/2021.02.22.431869 fatcat:oxb4xxbizndatmlwxcqljt6rgy

Tumour Cell Secretome in Chemoresistance and Tumour Recurrence

Emma C. Madden, Adrienne M. Gorman, Susan E. Logue, Afshin Samali
2020 Trends in Cancer  
We also highlight recent evidence describing how therapy-induced TCS can impact cancer stem cell (CSC) expansion and tumour-associated immune cells to enable tumour regrowth and antitumour immunity.  ...  Understanding how cancer cells overcome chemotherapy-induced cell death is critical in promoting patient survival.  ...  Disclaimer Statement A.M.G. and A.S. are cofounders, directors, and shareholders of Cell Stress Discoveries, Ltd.  ... 
doi:10.1016/j.trecan.2020.02.020 pmid:32460003 fatcat:ahizim2tf5cglhmks3hbl43tlq

JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2–Targeted Therapies

Simin Manole, Edward J. Richards, Aaron S. Meyer
2016 Cancer Research  
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. 2. Figure 2. Validation of variation in RTK bypass resistance capacity.  ...  therapies in lung carcinoma (6-10).  ...  This work was supported by NIH 1-DP5-OD019815-01 to A.S.M. and in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute.  ... 
doi:10.1158/0008-5472.can-16-0123 pmid:27450453 pmcid:PMC5026573 fatcat:4x6zq5jf7nfnbopfnyq3k24kqe

The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies

Morana Jaganjac, Lidija Milkovic, Suzana Borovic Sunjic, Neven Zarkovic
2020 Antioxidants  
Constant change by acquired mutations and metabolic reprogramming contribute to the high inter- and intratumor heterogeneity of malignant cells, their selective growth advantage, and their resistance to  ...  While cancer cells often produce more ROS due to their increased growth-favoring demands, numerous conventional anticancer therapies exploit this feature to ensure selective cancer cell death triggered  ...  Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer 2019, 134, 42-45. [CrossRef] 56.  ... 
doi:10.3390/antiox9111151 pmid:33228209 pmcid:PMC7699519 fatcat:k7xylmadsvgzxommhnayucb2pi

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

Abdulaziz B. Hamid, Ruben C. Petreaca
2020 Cancers  
Secondary resistant mutations in cancer cells arise in response to certain small molecule inhibitors. These mutations inevitably cause recurrence and often progression to a more aggressive form.  ...  The Catalogue of Somatic Mutations in Cancer (COSMIC) produced a compendium of resistant mutations to small molecule inhibitors reported in the literature.  ...  Acknowledgments: We thank James and Ellen Bazzoli for their generous donation to sponsor our laboratory. Conflicts of Interest: The authors declare no conflict of interest.  ... 
doi:10.3390/cancers12040927 pmid:32283832 pmcid:PMC7226513 fatcat:pvujprxicjgang3gwyivfojicy
« Previous Showing results 1 — 15 out of 2,052 results